Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now

Viatris Inc. (NASDAQ:VTRS) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, Viatris announced positive top-line results from a Phase 3 clinical trial of VR-205 (targeted-release budesonide) in Japanese adults with primary immunoglobulin A nephropathy (IgAN). The study met its primary endpoint, demonstrating a statistically significant 33.75% reduction in urine protein-to-creatinine ratio after nine months of treatment, while also showing improvements in kidney function and sustained proteinuria reduction.

The clinical profile observed in Japanese patients was consistent with results from previous global studies, and the treatment was reported to be well tolerated with no participants progressing to dialysis, kidney transplant, or severe renal impairment during the study. These findings represent a significant milestone for Viatris, as the company seeks to address the high incidence of IgAN in Japan, where it is a leading cause of chronic glomerulonephritis and end-stage renal disease.

Source: Unsplash

Building on these results, Viatris Inc. (NASDAQ:VTRS) is now targeting the submission of a NDA in Japan by the end of 2026. If approved, VR-205 would become the first IgAN-specific, targeted-release budesonide oral therapy in the country, providing a potentially disease-modifying treatment option for a condition that currently lacks curative therapies.

Viatris Inc. (NASDAQ:VTRS) is a healthcare company operating across Japan, Europe, Hong Kong, Africa, North America, Australia, the Middle East, New Zealand, Taiwan, Latin America, China, and the rest of Asia. The company operates through the JANZ, Developed Markets, Emerging Markets, and Greater China segments.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.